Autolus Limited
Clinical trials sponsored by Autolus Limited, explained in plain language.
Clinical-stage biopharmaceutical company developing CAR-T cell therapies.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Engineered immune cells take on lupus in first human test Results expected Sep 2027 (estimated)
-
Engineered immune cells take on lupus in first human test
Disease control OngoingThis early-phase trial is testing a one-time treatment called obecabtagene autoleucel (obe-cel) for people with severe lupus that hasn't improved with standard treatments. Obe-cel is made by taking a patient's own immune cells, engineering them to target and attack faulty B cells…
Phase 1 • Sponsor: Autolus Limited • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
Engineered immune cells take on tough leukemia in new trial
Disease control OngoingThis study tests a treatment called AUTO1, a type of CAR T cell therapy, in 153 adults whose B cell acute lymphoblastic leukemia has returned or not responded to standard treatments. The therapy involves taking a patient's own immune cells, engineering them to recognize and attac…
Phase 1/2 • Sponsor: Autolus Limited • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC